Which Company is Pioneering Cutting Edge Psychedelic-Assisted Treatments?

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Numinus is a Canadian-based mental health and wellness company focused on providing safe, legal access to breakthrough therapies using psychedelic substances like psilocybin, MDMA, Ketamine, LSD, and others. As one of the few companies to be licensed to produce, test, and distribute psychedelic treatments, Numinus has already established itself as an early leader in this high-growth industry. Here are some of the ways it's doing just that.

A 3-Pronged Approach Allows Numinus to Adapt to an Evolving Market

The market for psychedelic-assisted treatment is still young and highly constrained by regulation At such early stages, a company needs to be flexible and ready to pivot at a moment's notice. Moreover, it needs to take a proactive role in shaping future regulations and how the market develops. 

Numinus has prioritized this flexibility and proactive role by using a unique integrated approach to its business, involving these three branches:

• Numinus Bioscience: The company's lab for research into psychedelic substances as mental health treatments. This branch creates much of Numinus's intellectual property.
• Numinus R&D: The development side of the company which focuses on creating protocols for safe delivery of psychedelic treatments and encouraging policy reform to make treatments more accessible.
• Numinus Health: The consumer-facing end of the company which provides training, facilities, and other resources for delivering best-in-class care to patients.

By being actively engaged in all sides of the market, Numinus is uniquely positioned to play an active role in policy reform; define the standard of care and product development; and deliver treatment directly to patients. This provides many paths for revenue generation, both in the short term while regulations are still tight and later on as psychedelic treatments become more widely accessible. Moreover, Numinus is one of the few companies in the space already generating revenue, which it currently does through third-party testing and extraction services in its Bioscience lab; and through its clinics.

The First-Mover Advantage

As the first public company in Canada to receive a license for producing and extracting psilocybin, Numinus has enjoyed a significant first-mover advantage. Through Numinus Bioscience and Numinus R&D, the company continues to develop proprietary product formulas and testing methods. These proprietary products along with its standardized extraction methods are contracted out for use in research, clinical trials, and in the company's partnerships. 

Opportunities for Expansion

As the market works toward more widespread legalization, Numinus is already making plans to lead the charge in distribution. Through Numinus Health, the company plans to open a network of health centers where psychedelic-assisted therapy can be offered in a safe, controlled, and therapeutic environment tailored to patients' needs.

To achieve this vision, Numinus acquired Mindspace Psychology Services, Inc in February. Mindspace Psychology Services has a decade of experience in traditional clinic management and training. It has also made strides in the psychedelic-assisted treatment space by providing harm reduction and integration training to mental healthcare professionals.

With its recent IPO, investors have a great opportunity to invest in one of the leading companies shaping the emerging psychedelic treatment industry. It's well-diversified approach, recent acquisitions, cash on hand, and first-mover advantage all make Numinus one of the best choices for investors seeking to get into this new market early. 

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.